Emory University

Georgia Tech Research Corporation

Children's Healthcare of Atlanta, Inc.

Other

Queen's University at Kingston

Kingston Health Sciences Centre

Wake Forest University

Christopher B Doering

Anthony Atala

H Trent Spencer

Eric Gaucher

Harrison C Brown

Philip M Zakas

Harold Trent Spencer

Max Dale Cooper

Brantley R Herrin

Wilbur A Lam

David Myers

Caelan Radford

Reginald Tran

David Lillicrap

Christopher D Porada

Maria Graca N D Almeida-Porada

Trent H Spencer

The systems and methods are directed to leveraging the channel geometry and configuration to overcome diffusion limitations of current transduction systems. The methods may include a method of transducing target cells using a device. The device may include at least one continuous channel. The method may include delivering target cells and viral vectors into a transduction region of the channel. After transducing for some incubation time, a flushing solution may be delivered. The method may include collecting transduced cells after the transducing incubation time and the delivering of the flushing solution.

Methods, devices and systems for enhanced transduction efficiency

A recombinant von Willebrand Factor (VWF) protein comprising one or more mutations and uses thereof are described. A recombinant protein complex comprising a von Willebrand factor sequence and one artificial Factor VIII sequence is described. A recombinant protein complex comprising a Factor VIII sequence and one artificial von Willebrand sequence is described. A recombinant protein complex is described that includes one artificial von Willebrand factor sequence and one artificial Factor VIII sequence. Also described are nucleic acid sequences and a vector encoding a VWF sequence and a pharmaceutical composition for inducing blood clotting that includes a VWF protein.

Von Willebrand factor proteins for treating bleeding disorders

This disclosure relates to recombinant or chimeric FVIII proteins, variants, and vectors encoding the proteins containing one or more ancestral mutations. In certain embodiments, one or more protein domains comprise amino acid sequences that are derived from ancestrally reconstructed amino acid sequences. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising the proteins or vectors and related methods of inducing blood clotting.

Factor VIII proteins having ancestral sequences, expression vectors, and uses related thereto

Described are recombinant nucleic acid molecules for increased expression of Cas9 in human liver. In some embodiments, the recombinant nucleic acid molecules are provided in compositions and methods for gene editing, specifically using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR).

Cas9 nucleic acid molecules and their use

Disclosed herein are novel variants of clotting factors VII, VIII, and IX and their use, for example, in methods of treating a subject with a clotting disorder, such as hemophilia A or hemophilia B.

Nucleic acids encoding clotting factor variants and their use

This disclosure relates to recombinant cellular expression of chimeric proteins with peptide sequences derived from lymphocyte receptors and uses for treating cancer. In certain embodiments, the disclosure relates to a recombinant vector comprising a nucleic acid that encodes a chimeric protein with a segment with a targeting moiety based on a variable lymphocyte receptor (VLR) capable of binding a tumor associated antigen and a segment with a T cell signal transduction subunit. In certain embodiments, the recombinant vectors are used in immune based cancer treatments.

Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer

Disclosed herein are recombinant viral vectors comprising a liver specific promotor in operable combination with a heterologous nucleic acid sequence encoding a protein, such as a clotting factor. Methods of treating a subject with a clotting disorder, such as hemophilia A or hemophilia B, are also provided.

Recombinant promoters and vectors for protein expression in liver and use thereof

CAS9 nucleic acid molecules and their use

Embodiments of the present invention provide an integrated digital control apparatus () for a stringed musical instrument. In some embodiments, the apparatus () generally includes an input () coupled with at least a portion of the musical instrument, a digital control element () coupled with at least one of the instrument's pickups, and a controller () coupled with the input () and the digital control element (). The controller () is operable to control the digital control element () to vary at least one characteristic of the signal generated by the pickup in response to functioning of the input () by a musician. Such a configuration enables the musician to easily vary signal characteristics, such as volume or tone, while playing the instrument.

Integrated digital control for stringed musical instrument

Growing community of inventors

Atlanta, GA, United States of America

Christopher B Doering